1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Hungary Pharmaceuticals and Healthcare Report Q4 2015

Hungary Pharmaceuticals and Healthcare Report Q4 2015

  • August 2015
  • -
  • Business Monitor International
  • -
  • 110 pages

Includes 3 FREE quarterly updates

BMI View: Hungary's improving macroeconomic outlook and pledges by the government to raise
healthcare expenditure will boost pharmaceutical sales in the coming years. Consumer demand for overthe-counter medicines and greater uptake of generic medicines will be the primary drivers of pharmaceutical sales growth, as uptake of innovative drugs will remain hindered by the pricing sensitivity and budgetary constraints of the OEP national healthcare fund. However, Hungary's attractiveness to multinational drugmakers will remain impeded by onerous regulatory burden, pricing pressures and
punitive taxes on pharmaceutical companies.

Headline Expenditure Projections

- Pharmaceuticals: HUF640.21bn (USD2.75bn) in 2014 to HUF652.76bn (USD2.31bn) in 2015; +2.8% in local currency terms and -15.9% in US dollar terms.
- Healthcare: HUF2,382bn (USD10.23bn) in 2014 to HUF2,427bn (USD8.60bn) in 2015; +1.9% in local currency terms and -15.9% in US dollar terms.

Table Of Contents

Hungary Pharmaceuticals and Healthcare Report Q4 2015
BMI Industry View 7
SWOT 9
Political 11
Economic 12
Operational Risk 13
Industry Forecast 15
Pharmaceutical Market Forecast 15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Hungary 2011-2019) 16
Healthcare Market Forecast 17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Hungary 2011-2019) 19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Hungary 2011-2019) 20
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Hungary 2011-2019) 20
Prescription Drug Market Forecast 21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Hungary 2011-2019) 22
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Hungary 2011-2019) 24
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Hungary 2011-2019) 26
OTC Medicine Market Forecast 26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Hungary 2011-2019) 28
Pharmaceutical Trade Forecast 28
Table: Pharmaceutical Trade Data And Forecasts (Hungary 2013-2019) 30
Table: Pharmaceutical Trade Data And Forecasts local currency (Hungary 2013-2019) 30
Key Risks To BMI's Forecast Scenario 31
Macroeconomic Forecasts 32
Economic Analysis 32
Table: Economic Activity (Hungary 2010-2019) 39
Industry Risk Reward Indices 40
Central And Eastern Europe Risk/Reward Index - Q4 2015 40
Hungary Risk/Reward Index 46
Rewards 46
Risks 46
Market Overview 48
Industry Trends And Developments 50
Epidemiology 50
Healthcare System 53
Table: Healthcare Resources (Hungary 2009-2014) 55
Table: Healthcare Personnel (Hungary 2009-2014) 55
Table: Healthcare Activity (Hungary 2009-2014) 56
Healthcare Funding 56
Research and Development 57
Clinical Trials 57
Regulatory Development 60
Pharmaceutical Advertising 61
Intellectual Property Regime 62
Pricing Regime 63
Table: OEP Reimbursement Changes, September 2014 65
Pharmaceutical Mark-Ups 65
Table: Hungary - Pharmaceutical Price Build-Up (%) 66
Reimbursement Regime 66
Competitive Landscape 69
Company Profile 75
Egis Pharmaceuticals (Servier) 75
Eli Lilly 78
Gedeon Richter 81
GlaxoSmithKline 86
Merck and Co 88
Novartis 90
Pfizer 92
Sanofi 94
Teva 96
Demographic Forecast 99
Table: Population Headline Indicators (Hungary 1990-2025) 100
Table: Key Population Ratios (Hungary 1990-2025) 100
Table: Urban/Rural Population And Life Expectancy (Hungary 1990-2025) 101
Table: Population By Age Group (Hungary 1990-2025) 101
Table: Population By Age Group % (Hungary 1990-2025) 102
Glossary 104
Methodology 106
Pharmaceutical Expenditure Forecast Model 106
Healthcare Expenditure Forecast Model 106
Notes On Methodology 107
Risk/Reward Index Methodology 108
Index Overview 109
Table: Pharmaceutical Risk/Reward Index Indicators 109
Indicator Weightings 110

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.